Zhang Cheng, Li Yan, Zhang Ning, Sun Ju, Tian Deyu, Duan Xuefeng, Yang Jing, Bi Yuhai
College of Life Science and Technology, Xinjiang University, Urumchi, 830046, China.
Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, 100101, China.
Virol J. 2025 Jul 5;22(1):223. doi: 10.1186/s12985-025-02793-9.
H3N2 influenza A viruses [A(H3N2)] circulate as seasonal influenza in humans worldwide, resulting in a huge disease burden. Adaptation study of A(H3N2) in mice could provide a basis for preclinical evaluation of antivirals and vaccines targeting A(H3N2) and identify the genetic markers responsible for the viral adaptation, replication, and pathogenesis.
Lung-to-lung passaging of wild-type (WT) A(H3N2) strain was performed in C57BL/6J mice. Amino acid (AA) mutations occurred during the passaging and temporal dynamics of these mutations were identified using the next-generation sequencing. We determined the polymerase activity of the ribonucleoprotein (RNP) complex containing mutation genes and compared the pathogenicity between the mouse-adapted (MA) and A(H3N2)-WT strains based on body weight change, survival rate, lung index, lung viral load, and lung pathology of the infected mice.
The A(H3N2)-MA strain was obtained after seventeen lung-to-lung passages in mice. 14 AA mutations in the PB2, PB1, PA, HA, NP, and M1 genes were identified in the A(H3N2)-MA strain compared to the A(H3N2)-WT strain. In addition, the polymerase activity of the RNP complex containing mutation genes was increased, and the pathogenicity of the MA virus is significantly higher than that of the WT strain.
One A(H3N2)-MA strain has been developed that can infect and kill mice. The MA strain showed stronger replication ability and pathogenicity than the A(H3N2)-WT strain. This A(H3N2)-MA model provides a valuable basis for evaluating the effects of drugs and vaccines and for studying pathogenesis.
甲型H3N2流感病毒[A(H3N2)]作为季节性流感病毒在全球人类中传播,造成了巨大的疾病负担。对A(H3N2)在小鼠体内的适应性研究可为针对A(H3N2)的抗病毒药物和疫苗的临床前评估提供依据,并确定负责病毒适应性、复制和发病机制的遗传标记。
在C57BL/6J小鼠中进行野生型(WT)A(H3N2)毒株的肺对肺传代。传代过程中发生的氨基酸(AA)突变,并使用下一代测序确定这些突变的时间动态。我们测定了含有突变基因的核糖核蛋白(RNP)复合物的聚合酶活性,并根据感染小鼠的体重变化、存活率、肺指数、肺病毒载量和肺病理学比较了小鼠适应株(MA)和A(H3N2)-WT毒株之间的致病性。
在小鼠中进行17次肺对肺传代后获得了A(H3N2)-MA毒株。与A(H3N2)-WT毒株相比,在A(H3N2)-MA毒株中鉴定出PB2、PB1、PA、HA、NP和M1基因中的14个AA突变。此外,含有突变基因的RNP复合物的聚合酶活性增加,MA病毒的致病性明显高于WT毒株。
已培育出一种能感染并杀死小鼠的A(H3N2)-MA毒株。MA毒株比A(H3N2)-WT毒株表现出更强的复制能力和致病性。这种A(H3N2)-MA模型为评估药物和疫苗的效果以及研究发病机制提供了有价值的依据。